Such findings formed the basis for the clinical use of monoclonal antibodies directed against TNFα for the treatment of RA and other forms of immune arthritis, starting from infliximab, the first chimeric anti-TNFα, and further arriving at similar biological agents, such as adalimumab, golimumab, certolizumab, and etanercept. Here, TNF is linked to rheumatoid arthritis.